Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

as compared to Q3 2010.

2.    Royalties

Year on year growth Royalties to Product Shire $M Royalties CER ADDERALL XR 1.00 22.9 27% 27% 3TC and ZEFFIX 1.00 17.3 -57% -58% FOSRENOL 1.00 10.9 56% 56% Other 1.00 11.7 7% 0% Total 1.00 62.8 -18% -19%

Royalty income decreased in Q3 2011 compared to Q3 2010 as higher royalties on ADDERALL XR and FOSRENOL were more than offset by lower royalties from 3TC and ZEFFIX.

Royalty income from 3TC and ZEFFIX continues to be adversely impacted by increased competition from other products. Additionally, in Q3 2011 Shire has continued to not recognize royalty income for 3TC for certain territories due to a disagreement between GSK and Shire about how the relevant royalty rate should be applied given the expiry dates of certain patents. In Q3 2011 this disagreement extended to ZEFFIX, and accordingly Shire has not recognized ZEFFIX royalty income for the affected territories. GSK and Shire continue to hold discussions in order to clarify this issue.

3.    Financial details

Cost of product sales

% of % of product product Q3 2011 sales Q3 2010 sales $M $M Cost of product sales (US GAAP) 166.5 16% 112.7 14% Unwind of DERMAGRAFT inventory fair value step-up on acquisition (9.0) - Transfer of manufacturing from Owings Mills (3.4) (7.3) Depreciation (8.6) (2.3) Cost of product sales (Non GAAP) 145.5 14% 103.1 13%

Non GAAP cost of product sales as a percentage of product sales increased in Q3 2011 compared to the same period in 2010 due to the inclusion of DERMAGRAFT and the impact of a $10.0 million inventory write down of expired ELAPRASE unpurified bulk material, which was not prioritised for purification as capacity was directed towards meeting demand for REPLAGAL and VPRIV.

US GAAP cost of product sales as a percentage of product sales was two percentage points higher than the same period in 2010 due to the ELAPRASE write dow
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Smarter ... outdoor security solutions, today announced that Genzyme, a Sanofi ... units of Door Detective® CL for a multi-use facility ... installed in four other Genzyme buildings, this latest order ... with the tailgate detection device improving doorway ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... May 21, 2013 NANONEX CORPORATION, ... solutions , today announced the successful delivery and ... system, the NX-M200B, to a major Japanese manufacturing ... a fully-automated, production-ready, advanced nanoimprint lithography tool that ... wafer and substrate sizes and types. Based on ...
(Date:5/21/2013)... 2013 PathoGenetix, Inc., a commercial-stage developer ... announced today that it has successfully identified and strain ... obtained from the Centers for Disease Control and Prevention ... The findings are detailed in a poster ... for Microbiology in Denver on Monday. , The 250 ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... (Nasdaq: BCRX ) today announced that it ... Industry conference in New,York. A live webcast of ... 2:00 p.m. Eastern Time may be accessed at ... be archived for seven days. (Logo: ...
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) today announced ... at the 2007 UBS Global Life Sciences,Conference which ... York on Wednesday,September 26 at 1:30 p.m. EDT. ... webcast of the presentation will be accessible through ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... Research in Oral Biology Award will be presented to ... at the International Association for Dental Research (IADR) 87th ... 1, 2009. , Dr. McCulloch has been professor in ... He also serves as Director of,the Canadian Institutes of ...
... medulloblastoma, the most frequent malignant brain tumor in childhood, ... spread and what the chances of disease relapse are. ... at the Heidelberg University Hospital and the German Cancer ... set of tumor markers, the intensity of treatment can ...
... American Association for Cancer Research extends its sincere ... to lead the Food and Drug Administration (FDA). ... advancement of cutting-edge products and therapies that are ... Her leadership will bring new perspectives to important ...
Cached Biology News:New tumor markers determine therapy intensity 2New tumor markers determine therapy intensity 3
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
... system, which is based on a new flow-through ... performing in situ hybridization of tissues on microscope ... the study of gene expression, in situ hybridization ... and can be used to validate and confirm ...
... Software has been optimized for the analysis ... the software to quickly and accurately locate ... of an ELISA plate or each section ... has been customized to incorporate standard ELISA ...
... a dual strength adhesive system which facilitates the ... adhesives on either side of the frame are ... the glass has an easy release adhesive whereas ... a stronger bond. This means that when the ...
Biology Products: